I Mab Stock Quote Today


USD 3.70  0.12  3.14%   

Market Performance
0 of 100
Odds Of Distress
Less than 12
I Mab is trading at 3.70 as of the 3rd of December 2022, a -3.14 percent decrease since the beginning of the trading day. The stock's open price was 3.82. I Mab has less than a 12 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for I-Mab are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of December 2021 and ending today, the 3rd of December 2022. Click here to learn more.
Fiscal Year End
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
17th of January 2020
Health Care
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. The company was founded in 2014 and is headquartered in Shanghai, the Peoples Republic of China. I-Mab ADR operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 83.1 M outstanding shares of which 2.13 M shares are currently shorted by private and institutional investors with about 6.47 trading days to cover. More on I-Mab

Moving together with I Mab

+0.71ACBAurora Cannabis Aggressive PushPairCorr
+0.75ARWRArrowhead Pharmaceuticals Upward RallyPairCorr
+0.81BEAMBeam TherapeuticsInc Normal TradingPairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

I Mab Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. I Mab's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding I Mab or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
I-Mab generated a negative expected return over the last 90 days
I-Mab has high historical volatility and very poor performance
The company reported the previous year's revenue of 88.03 M. Net Loss for the year was (2.33 B) with profit before overhead, payroll, taxes, and interest of 41.59 M.
I-Mab currently holds about 3.92 B in cash with (973.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 47.2, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Fama & French Classification
Average Analyst Recommendation
Analysts covering I Mab report their recommendations after researching I Mab's financial statements, talking to executives and customers, or listening in on I Mab's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering I-Mab. The I Mab consensus assessment is calculated by taking the average forecast from all of the analysts covering I Mab.
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of I Mab's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellUndervalued
I-Mab (IMAB) is traded on NASDAQ Exchange in USA and employs 378 people. I Mab is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with current market capitalization of 306.63 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate I Mab's market, we take the total number of its shares issued and multiply it by I Mab's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. I-Mab conducts business under Biotechnology sector and is part of Health Care industry. The entity has 83.1 M outstanding shares of which 2.13 M shares are currently shorted by private and institutional investors with about 6.47 trading days to cover. I-Mab currently holds about 3.92 B in cash with (973.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 47.2, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check I Mab Probability Of Bankruptcy
I Mab secures a total of 83.1 Million outstanding shares. Over half of I-Mab outstanding shares are owned by outside corporations. These outside corporations are typically referred to corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Therefore, these institutions are subject to different rules and regulation than regular investors in I-Mab. Please watch out for any change in the institutional holdings of I Mab as this could mean something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check I Mab Ownership Details

I Mab Stock Price Odds Analysis

What are I Mab's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of I Mab jumping above the current price in 90 days from now is about 77.43%. The I-Mab probability density function shows the probability of I Mab stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.462. This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, I Mab will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. I-Mab is significantly underperforming NYSE Composite.
  Odds Below 3.7HorizonTargetOdds Above 3.7
22.49%90 days
Based on a normal probability distribution, the odds of I Mab to move above the current price in 90 days from now is about 77.43 (This I-Mab probability density function shows the probability of I Mab Stock to fall within a particular range of prices over 90 days) .

I Mab Stock Institutional Holders

Institutional Holdings refers to the ownership stake in I Mab that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of I Mab's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing I Mab's value.
InstituionSecurity TypeTotal SharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares2.3 KK
Zurcher Kantonalbank Zurich CantonalbankCommon Shares2.3 K26 K
View I Mab Diagnostics

I-Mab Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. I Mab market risk premium is the additional return an investor will receive from holding I Mab long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in I Mab. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although I Mab's alpha and beta are two of the key measurements used to evaluate I Mab's performance over the market, the standard measures of volatility play an important role as well.

I Mab Stock Against Markets

Picking the right benchmark for I Mab stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in I Mab stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for I Mab is critical whether you are bullish or bearish towards I-Mab at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in I Mab without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Companies Directory Now


Companies Directory

Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
All  Next Launch Module

I Mab Corporate Management

Elected by the shareholders, the I Mab's board of directors comprises two types of representatives: I Mab inside directors who are chosen from within the company, and outside directors, selected externally and held independent of I Mab. The board's role is to monitor I Mab's management team and ensure that shareholders' interests are well served. I Mab's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, I Mab's outside directors are responsible for providing unbiased perspectives on the board's policies.
Tianyi Zhang - VP RelationsProfile
Richard MBA - COO CFOProfile
Weiming Tang - Exec OfficerProfile
Jingwu MD - Founder ChairmanProfile
Jerry Wang - CoFounder OfficerProfile
Ivan Zhu - Chief OfficerProfile
Cheng Li - Chief OfficerProfile

Invested in I-Mab?

The danger of trading I-Mab is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of I Mab is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than I Mab. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile I-Mab is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please see Risk vs Return Analysis. Note that the I-Mab information on this page should be used as a complementary analysis to other I Mab's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Valuation module to check real value of public entities based on technical and fundamental data.

Complementary Tools for I Mab Stock analysis

When running I-Mab price analysis, check to measure I Mab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy I Mab is operating at the current time. Most of I Mab's value examination focuses on studying past and present price action to predict the probability of I Mab's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move I Mab's price. Additionally, you may evaluate how the addition of I Mab to your portfolios can decrease your overall portfolio volatility.
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Is I Mab's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of I Mab. If investors know I Mab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about I Mab listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
306.6 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of I-Mab is measured differently than its book value, which is the value of I Mab that is recorded on the company's balance sheet. Investors also form their own opinion of I Mab's value that differs from its market value or its book value, called intrinsic value, which is I Mab's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because I Mab's market value can be influenced by many factors that don't directly affect I Mab's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between I Mab's value and its price as these two are different measures arrived at by different means. Investors typically determine I Mab value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, I Mab's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.